Return to Listing

22 result(s) for Gastrointestinal Cancers

PI Name Protocol # Title
Vassiliki Tsikitis IRB00003082 Oregon Colorectal Cancer Registry
Brett Sheppard IRB00003609 Oregon Pancreas Tissue Registry
Kevin Billingsley IRB00005222 Oregon Liver Tumor Registry
David Lieberman IRB00006137 PVAMC / OHSU: Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients
Rodney Pommier IRB00009420 Oregon Index of Endocrine Neoplasias (ORION)
Erin Gilbert IRB00009694 The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer
Daniel Herzig IRB00011161 A Phase II Multicenter Randomized Trial Evaluating 3-Year Disease-Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy, and Total Mesorectal Excision or Non-Operative Management
Gina Vaccaro IRB00011256 Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer
Gina Vaccaro IRB00011746 I4T-MC-JVDE: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
Gina Vaccaro IRB00011974 A Randomized Controlled Trial of Transcatheter Arterial Chemoembolization with Drug-Eluting Beads (DEB-TACE) Versus Sorafenib in the Treatment of Unresectable, Locally-Advanced Hepatocellular Carcinoma
Alexander Guimaraes IRB00012071 A Pilot Study Using a Novel Imaging of Lymph Nodes in Patients with Locally Advanced Esophageal Cancer Using Ferumoxytol Enhanced MRI
Gina Vaccaro STUDY00015077 9785-CL-3021: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma
Jeremy Cetnar STUDY00015218 A Phase 3 Prospective, Randomized, Double-Blind, Multi-Center, Study Of The Efficacy And Safety Of Lanreotide Autogel/ Depot 120mg Plus BSC Vs Placebo Plus BSC For Tumor Control In Subjects With Well-Differentiated, Metastatic And/Or Unresectable Typical Or Atypical Lung Neuroendocrine Tumors
Charles Lopez STUDY00015304 CC #144525: Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
Gina Vaccaro STUDY00015439 A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)
Gina Vaccaro STUDY00015495 A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Brett Sheppard STUDY00015705 The OHSU Pancreas Community Registry
Gina Vaccaro STUDY00015706 EMR100070-007: A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction
Gina Vaccaro STUDY00015816 A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)
Gina Vaccaro STUDY00016058 CA209-577: A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 577)
Raymond Bergan STUDY00016113 Molecular Mechanisms of Tumor Evolution and Resistance to Therapy
Gina Vaccaro STUDY00016133 A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080